
Roche has announced encouraging early results from its phase 1/2 trial of NXT007, an investigational bispecific antibody for haemophilia A. …
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns

